Manava Plus develops neural prostheses using spinal organoids on a microchip with AI control to restore disrupted circuits caused by spinal cord and brain injuries. Their technology aims to enable patients with neurological impairments to regain motor function and sensation.
Funding
Funding not disclosed
Founders
Product
Problem
Spinal cord injuries (SCI) result in disrupted neural circuits, leading to loss of motor and sensory functions. Current treatments for SCI are often ineffective, significantly reducing the patient's quality of life and resulting in high lifetime healthcare costs.
Solution
Manava Plus develops bio-hybrid neural prostheses to regenerate and reconnect nervous systems damaged by spinal cord injuries, with the goal of restoring motor and sensory functions. The technology combines the patient's own cells with AI-driven biomimetic stimulation to deliver personalized treatments. These neural prostheses utilize 3D organoids derived from the patient’s cells to replicate spinal cord tissue and restore lost neural connections. Bioengineered 3D scaffolds embed bioelectronic structures, enhancing body integration and supporting neural regeneration. An AI system processes neural signals to and from the brain, continuously adapting stimulation in real time for optimal patient response.
Target Audience
The primary target audience includes individuals with spinal cord injuries seeking to restore motor and sensory functions.
Features
- 3D organoids derived from patient's own cells to replicate spinal cord tissue
- Bioengineered 3D scaffolds to enhance body integration
- AI-driven biomimetic stimulation for personalized treatment
- Organoids-on-a-chip to process neural signals
- Real-time adaptation of stimulation for optimal patient response